Comparable stake leader
Roivant Sciences Ltd.
SEC ownership of Immunovant, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001764013.
Disclosed value leader
Roivant Sciences Ltd.
Comparable rows
3/50
Latest evidence
01 Oct 2026
- Public ticker
- IMVT on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Roivant Sciences Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
3 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Roivant Sciences Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
01 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001764013
- Issuer location
- Durham, NC
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Immunovant, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Roivant Sciences Ltd.
Disclosed value leader
Roivant Sciences Ltd.
Comparable rows
3/50
Latest evidence
01 Oct 2026
13D/G
3/4/5
13F
Lead comparable stake: 56%
47 rows are not safely comparable across share classes.
13D/G row: Roivant Sciences Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Roivant Sciences Ltd. leads the comparable SEC ownership view at 56%.
3 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Roivant Sciences Ltd.'s linked filing trail.
Comparable ownership
Top 3
Roivant Sciences Ltd.
56%
FMR LLC
8.4%
Deep Track Capital, LP
4.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. |
13D/G
3/4/5
Director, 10%+ Owner
|
56%
Reported 13D/G
· 12 Dec 2025
|
$2,812,776,314
113,327,007 shares
|
+$413,666,650 | 12 Dec 2025 |
| FMR LLC |
13F
13D/G
Company
|
8.4%
Reported 13D/G
· 30 Sep 2025
|
$623,664,634
16,186,469 shares
|
— | 30 Jun 2026 |
| Deep Track Capital, LP |
13D/G
13F
Company
|
4.6%
Reported 13D/G
· 30 Jun 2026
|
$361,502,544
9,341,151 shares
|
-$6,147,456 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
—
denominator unverified
|
$276,679,973
7,180,897 shares
|
— | 30 Jun 2026 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13F
Company
|
—
denominator unverified
|
$223,666,650
5,805,000 shares
|
— | 30 Jun 2026 |
| BAKER BROS. ADVISORS LP |
13F
Company
|
—
denominator unverified
|
$209,419,027
5,435,220 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
Company
|
—
denominator unverified
|
$177,893,203
4,617,005 shares
|
— | 30 Jun 2026 |
| MORGAN STANLEY |
13F
Company
|
—
denominator unverified
|
$174,727,164
4,534,833 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$333,495,701.
Buys
$349,999,986
Insiders: 1
Sells
$16,504,285
Insiders: 9
Net
+$333,495,701
Shares: +16,156,719
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 16,666,666
Shares: 509,947
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 27,486 | $0 | $922,805 | -$922,805 |
| 3-6 | 0 | 343,214 | $0 | $12,029,238 | -$12,029,238 |
| 6-9 | 0 | 75,379 | $0 | $2,013,832 | -$2,013,832 |
| 9-12 | 16,666,666 | 63,868 | $349,999,986 | $1,538,410 | +$348,461,576 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Immunovant, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Roivant Sciences Ltd.
Net 12M change
+$333.5M
Full value: +$333,495,702 · USD · 12-month changeLatest report
28 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director, 10%+ Owner | $2,379,657,147 | +$349,999,986 | +17% | Filing P/S | 12 Dec 2025 |
| Frank Torti | Director | $25,068,718 | Mixed | 07 Apr 2026 | ||
| Peter Salzmann | Chief Executive Officer, Director | $17,543,264 | Filing P/S | 16 Apr 2025 | ||
| Julia G. Butchko | Chief Development Officer | $14,251,795 | Filing P/S | 21 Aug 2024 | ||
| Eric Venker | Chief Executive Officer, Director | $8,768,828 | -$581,424 | -6.2% | Filing P/S | 01 Oct 2026 |
| Mark S. Levine | Chief Legal Officer | $8,124,353 | Filing P/S | 20 Nov 2024 | ||
| William L. Macias | Chief Medical Officer | $7,454,384 | Filing P/S | 19 Feb 2025 | ||
| Melanie Gloria | Chief Operating Officer | $6,958,943 | -$1,671,996 | -19% | Filing P/S | 07 Oct 2026 |
| Tiago Girao | Chief Financial Officer | $6,674,472 | -$1,598,897 | -19% | Filing P/S | 28 Oct 2026 |
| Eva Renee Barnett | Chief Financial Officer | $5,907,965 | Filing P/S | 16 Apr 2025 | ||
| Atul Pande | Director | $5,821,550 | -$424,650 | -6.8% | Mixed | 28 Aug 2026 |
| Jay S. Stout | Chief Technology Officer | $5,757,236 | -$2,394,514 | -29% | Filing P/S | 21 Oct 2026 |
| Christopher van Tuyl | Chief Legal Officer | $5,617,489 | -$1,460,859 | -21% | Filing P/S | 07 Oct 2026 |
| Michael Geffner | Chief Medical Officer | $4,147,740 | Filing P/S | 22 Oct 2025 | ||
| Douglas J. Hughes | Director | $3,344,713 | -$348,665 | -9.4% | Mixed | 07 Apr 2026 |
| George Migausky V | Director | $2,739,530 | Mixed | 01 Apr 2025 | ||
| Andrew J. Fromkin | Director | $2,496,259 | -$7,955,300 | -76% | Filing P/S | 28 May 2026 |
| Robert Graham Susman | Director | $988,824 | -$67,979 | -6.4% | Filing P/S | 01 May 2026 |
| Jake Bauer | Director | $966,157 | Mixed | 07 Apr 2026 |
Recent insider transactions for Immunovant, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Tiago Girao | IMVT | Common Stock | Sale | -2.74% | -$188,271 | $28.50 | -6,606 | 234,192 | 28 Oct 2026 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -1.29% | -$75,099 | $28.94 | -2,595 | 198,937 | 21 Oct 2026 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -1.85% | -$122,117 | $32.06 | -3,809 | 201,532 | 07 Oct 2026 | Direct |
| Christopher van Tuyl | IMVT | Common Stock | Sale | -0.75% | -$42,544 | $32.06 | -1,327 | 175,218 | 07 Oct 2026 | Direct |
| Melanie Gloria | IMVT | Common Stock | Sale | -1.02% | -$71,846 | $32.06 | -2,241 | 217,060 | 07 Oct 2026 | Direct |
| Eric Venker | IMVT | Common Stock | Sale | -1.35% | -$119,590 | $34.11 | -3,506 | 257,075 | 02 Oct 2026 | Direct |
| Eric Venker | IMVT | Common Stock | Disposed to Issuer | -24.8% | -85,886 | 260,581 | 01 Oct 2026 | Direct | ||
| Eric Venker | IMVT | Common Stock | Options Exercise | 36.2% | 92,187 | 346,467 | 01 Oct 2026 | Direct | ||
| Eric Venker | IMVT | Capped Value Appreciation Rights | Options Exercise | -9.09% | -92,187 | 921,875 | 01 Oct 2026 | Direct | ||
| Christopher van Tuyl | IMVT | Common Stock | Sale | -1.59% | -$103,481 | $36.36 | -2,846 | 176,545 | 23 Sep 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Sale | -1.27% | -$64,905 | $43.27 | -1,500 | 116,731 | 28 Aug 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Options Exercise | 1.29% | 1,500 | 118,231 | 28 Aug 2026 | Direct | ||
| Atul Pande | IMVT | Stock Option (right to buy) | Options Exercise | -2.25% | -1,500 | 65,181 | 28 Aug 2026 | Direct | ||
| Melanie Gloria | IMVT | Common Stock | Sale | -1.37% | -$134,953 | $44.16 | -3,056 | 219,301 | 20 Aug 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Sale | -1.27% | -$59,700 | $39.80 | -1,500 | 116,731 | 24 Jul 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Options Exercise | 1.29% | 1,500 | 118,231 | 24 Jul 2026 | Direct | ||
| Atul Pande | IMVT | Stock Option (right to buy) | Options Exercise | -2.2% | -1,500 | 66,681 | 24 Jul 2026 | Direct | ||
| Tiago Girao | IMVT | Common Stock | Sale | -2.75% | -$263,015 | $38.69 | -6,798 | 240,798 | 23 Jul 2026 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -1.37% | -$110,537 | $38.69 | -2,857 | 205,341 | 23 Jul 2026 | Direct |
| Melanie Gloria | IMVT | Common Stock | Sale | -0.91% | -$80,532 | $39.55 | -2,036 | 222,357 | 08 Jul 2026 | Direct |
| Christopher van Tuyl | IMVT | Common Stock | Sale | -0.67% | -$47,702 | $39.55 | -1,206 | 179,391 | 08 Jul 2026 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -1.65% | -$137,925 | $39.55 | -3,487 | 208,198 | 08 Jul 2026 | Direct |
| Eric Venker | IMVT | Common Stock | Sale | -1.2% | -$118,980 | $38.48 | -3,092 | 254,280 | 02 Jul 2026 | Direct |
| Eric Venker | IMVT | Common Stock | Disposed to Issuer | -25.2% | -86,629 | 257,372 | 01 Jul 2026 | Direct | ||
| Eric Venker | IMVT | Common Stock | Options Exercise | 36.6% | 92,188 | 344,001 | 01 Jul 2026 | Direct | ||
| Eric Venker | IMVT | Capped Value Appreciation Rights | Options Exercise | -8.33% | -92,188 | 1,014,062 | 01 Jul 2026 | Direct | ||
| Melanie Gloria | IMVT | Common Stock | Sale | -7.32% | -$678,604 | $38.31 | -17,714 | 224,393 | 26 Jun 2026 | Direct |
| Jay S. Stout | IMVT | Common Stock | Sale | -15.9% | -$1,532,309 | $38.31 | -40,000 | 211,685 | 26 Jun 2026 | Direct |
| Christopher van Tuyl | IMVT | Common Stock | Sale | -8.98% | -$682,887 | $38.31 | -17,824 | 180,597 | 26 Jun 2026 | Direct |
| Christopher van Tuyl | IMVT | Common Stock | Options Exercise | 9.87% | 17,824 | 198,421 | 26 Jun 2026 | Direct | ||
| Christopher van Tuyl | IMVT | Stock Option (right to buy) | Options Exercise | -24.9% | -17,824 | 53,707 | 26 Jun 2026 | Direct | ||
| Tiago Girao | IMVT | Common Stock | Sale | -3.88% | -$384,600 | $38.46 | -10,000 | 247,596 | 26 Jun 2026 | Direct |
| Tiago Girao | IMVT | Common Stock | Options Exercise | 4.04% | 10,000 | 257,596 | 26 Jun 2026 | Direct | ||
| Tiago Girao | IMVT | Stock Option (right to buy) | Options Exercise | -3.41% | -10,000 | 283,505 | 26 Jun 2026 | Direct | ||
| Atul Pande | IMVT | Common Stock | Sale | -1.27% | -$57,015 | $38.01 | -1,500 | 116,731 | 26 Jun 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Options Exercise | 1.29% | 1,500 | 118,231 | 26 Jun 2026 | Direct | ||
| Atul Pande | IMVT | Stock Option (right to buy) | Options Exercise | -2.15% | -1,500 | 68,181 | 26 Jun 2026 | Direct | ||
| Christopher van Tuyl | IMVT | Common Stock | Sale | -1.44% | -$93,217 | $35.39 | -2,634 | 180,597 | 18 Jun 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Sale | -1.27% | -$51,030 | $34.02 | -1,500 | 116,731 | 15 Jun 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Options Exercise | 1.29% | 1,500 | 118,231 | 15 Jun 2026 | Direct | ||
| Atul Pande | IMVT | Stock Option (right to buy) | Options Exercise | -2.11% | -1,500 | 69,681 | 15 Jun 2026 | Direct | ||
| Andrew J. Fromkin | IMVT | Common Stock | Sale | -74.9% | -$7,438,111 | $33.51 | -221,951 | 74,382 | 28 May 2026 | Direct |
| Andrew J. Fromkin | IMVT | Common Stock | Options Exercise | 197.1% | 196,601 | 296,333 | 28 May 2026 | Direct | ||
| Andrew J. Fromkin | IMVT | Stock Option (right to buy) | Options Exercise | -100% | -196,601 | 0 | 28 May 2026 | Direct | ||
| Melanie Gloria | IMVT | Common Stock | Sale | -1.27% | -$101,072 | $32.45 | -3,115 | 242,107 | 20 May 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Sale | -4.89% | -$192,000 | $32.00 | -6,000 | 116,731 | 20 May 2026 | Direct |
| Atul Pande | IMVT | Common Stock | Options Exercise | 5.14% | 6,000 | 122,731 | 20 May 2026 | Direct | ||
| Atul Pande | IMVT | Stock Option (right to buy) | Options Exercise | -2.17% | -6,000 | 270,252 | 20 May 2026 | Direct | ||
| Robert Graham Susman | IMVT | Common Stock | Sale | -6.43% | -$67,979 | $27.17 | -2,502 | 36,394 | 01 May 2026 | Direct |
| Tiago Girao | IMVT | Common Stock | Sale | -9.42% | -$763,011 | $29.62 | -25,760 | 247,596 | 23 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.